MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• The Murine Double Minute 2 (MDM2) gene product is an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53.
• MDM2 overexpression is implicated in various cancers, leading to reduced p53 activity, tumor initiation, and therapeutic resistance.
• MDM2 also possesses p53-independent functions crucial for cell cycle progression and DNA repair.

Purpose of the Study:

• To review clinical trials investigating MDM2 inhibition as a cancer therapy.
• To highlight the therapeutic potential of targeting the MDM2-p53 interaction.
• To discuss MDM2's role in cancers with wild-type TP53.

Main Methods:

• Review of clinical trial data on MDM2 inhibitors.
• Analysis of MDM2's mechanism of action, including p53-dependent and independent pathways.
• Examination of MDM2 expression patterns in various malignancies.

Main Results:

• Elevated MDM2 expression correlates with poor prognosis in cancers like liposarcoma, breast cancer, and glioblastoma.
• MDM2 inhibitors are in clinical development to disrupt the MDM2-p53 interaction.
• Restoring p53 tumor-suppressive functions via MDM2 inhibition is a key therapeutic strategy.

Conclusions:

• MDM2 is a validated therapeutic target in oncology.
• MDM2 inhibitors show promise for reactivating p53 in tumors with wild-type TP53.
• Targeting MDM2 offers a potential strategy to improve cancer treatment outcomes.